Search

Brilaroxazine

Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.

Dilmapimod

Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

GC-373

GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, [GC-376 free acid][A219031,A219036].

Dalfampridine

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

Dihydroergocornine

Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects. It is an artificial derivative of the crude extract of ergot and later purified, ergocornine. The formation of dihydroergocornin...

Orforglipron

Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecu...

Oxprenolol

A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

Allylestrenol

A synthetic steroid with progestational activity. It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast...

Phosphate ion

Ciltacabtagene autoleucel

[A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]